LexaGene Announces MiQLab® System Sale to Veterinary Hospital in Wisconsin
01 July 2022 - 9:45PM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), a molecular diagnostics company that
has commercialized the MiQLab® System for automated, multiplexing
PCR-based syndromic testing in veterinary clinics, is pleased to
announce that it has entered into a purchase agreement with a
veterinary hospital in Wisconsin.
Dr. Jack Regan, LexaGene’s CEO and Founder
stated, “We are pleased to announce this sale to a veterinary
hospital in Wisconsin. Once we complete our scheduled
installations, we will have MiQLab Systems operating in 10 states
across the US. Since the start of this year, our install base has
increased 240% and we expect an even steeper increase in the latter
part of this year.”
To learn more about LexaGene and the MiQLab
System or subscribe to company updates, visit www.lexagene.com, or
follow us on Twitter or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
To learn more about LexaGene and the MiQLab
System or subscribe to company updates, visit www.lexagene.com, or
follow us on Twitter or LinkedIn.
For inquiries: 800.215.1824 | ir@lexagene.com or
info@lexagene.com
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that
develops molecular diagnostic systems for pathogen detection and
genetic testing for other molecular markers for on-site rapid
testing in veterinary diagnostics, food safety and for use in
open-access markets such as clinical research, agricultural testing
and biodefense. End-users simply need to collect a sample, load it
onto the instrument with a sample preparation cartridge, enter
sample ID and press ‘go’. The MiQLab® system delivers excellent
sensitivity, specificity, and breadth of detection and can return
results in approximately two hours. The unique open-access feature
is designed for custom testing so that end-users can load their own
real-time PCR assays onto the instrument to target any genetic
target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors -- including the
availability of funds, the results of financing efforts, the
success of technology development efforts, the cost to procure
critical parts, performance of the instrument, market acceptance of
the technology, regulatory acceptance, and licensing issues -- that
could cause actual results to differ materially from the Company's
expectations as disclosed in the Company's documents filed from
time to time on SEDAR (see www.sedar.com). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The company disclaims any intention or obligation, except to the
extent required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Lexagene (TSXV:LXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Apr 2023 to Apr 2024